Central Pharmaceuticals Ltd. (DSE:CENTRALPHL)

Central Pharmaceuticals Income Statement

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	33.06	29.6	29.33	26	148.15
Revenue Growth (YoY)	11.68%	0.93%	12.81%	-82.45%	5.75%
Cost of Revenue	44.19	50.21	58.36	63.58	118.89
Gross Profit	-11.13	-20.61	-29.03	-37.58	29.27
Selling, General & Admin	11.57	16.65	18.83	15.77	22.45
Other Operating Expenses	-	0.44	-	-	-
Operating Expenses	11.57	17.09	18.83	15.77	22.45
Operating Income	-22.7	-37.7	-47.86	-53.35	6.82
Interest Expense	-	-	-	-17.36	-21.36
Interest & Investment Income	0.01	0.01	0	0	0.01
Other Non Operating Income (Expenses)	-0.01	-0.01	-0.01	-0.11	-0.09
EBT Excluding Unusual Items	-22.7	-37.71	-47.87	-70.82	-14.63
Asset Writedown	-	-10.59	-	-	-
Pretax Income	-22.7	-48.3	-47.87	-70.82	-14.63
Income Tax Expense	-0.72	-5.88	-3.91	-2.57	-6.16
Net Income	-21.98	-42.42	-43.96	-68.25	-8.47
Net Income to Common	-21.98	-42.42	-43.96	-68.25	-8.47
Shares Outstanding (Basic)	120	120	120	120	120
Shares Outstanding (Diluted)	120	120	120	120	120
EPS (Basic)	-0.18	-0.35	-0.37	-0.57	-0.07
EPS (Diluted)	-0.18	-0.35	-0.37	-0.57	-0.07
Free Cash Flow	-0.52	2.97	-0.33	-1.12	-4.78
Free Cash Flow Per Share	-0.00	0.03	-0.00	-0.01	-0.04
Gross Margin	-33.66%	-69.62%	-98.99%	-144.57%	19.75%
Operating Margin	-68.66%	-127.37%	-163.18%	-205.21%	4.60%
Profit Margin	-66.49%	-143.31%	-149.88%	-262.51%	-5.72%
Free Cash Flow Margin	-1.57%	10.02%	-1.11%	-4.31%	-3.22%
EBITDA	-1.08	-24.25	-21.11	-23.59	39.71
EBITDA Margin	-3.28%	-81.92%	-71.98%	-90.75%	26.80%
D&A For EBITDA	21.61	13.45	26.75	29.76	32.89
EBIT	-22.7	-37.7	-47.86	-53.35	6.82
EBIT Margin	-68.66%	-127.37%	-163.18%	-205.21%	4.60%

Updated Dec 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.